Morph India

Study Highlights

- Principal Investigator: Dr. Deepak Davidson
- The objective of the study is to evaluate safety and performance of the BioMime™ Morph Sirolimus-Eluting Coronary Stent System in very long (length ≤ 56 mm) coronary lesions in native coronary arteries with reference vessel diameter of 2.25 mm to 3.50 mm
- Freedom from TLF was reported 98.39% at 6-month follow-up



❖ Study Design

- **A prospective, multi-centre, single arm, observational, real-world registry**



A total of 435 subjects to be enrolled from 19 sites across India

Follow-up at 1 month, 6 months, 12 months and 24 months post-procedure



Angiographic follow-up at 9 months
Analysed by CBCC Global Research LLP, Ahmedabad, India



OCT follow-up at 6 months
Analysed by CBCC Global Research LLP, Ahmedabad, India

❖ Study Results



Figure 1: Cardiac Status



Figure 2: Lesion location



Figure 3: Stent length



Figure 4: Stent diameter



Figure 5: Event Description

❖ Reference

1. Clinical Trial Registration NCT02901353: https://clinicaltrials.gov/ct2/show/NCT02901353?term=NCT02901353&draw=2&rank=1.
2. Davidson D. Safety and Performance of the World's First Tapered Coronary Stent for Long Coronary Lesions: Six-month Experience in Real World Settings. TCT-2019.
3. Davidson D. Clinical outcome of the world's first tapered sirolimus-eluting coronary stent system for long coronary lesions: a real-world experience. EuroIntervention 2020.